K-numberK242672
Device nameZoom System
ApplicantImperative Care, Inc.
Product codeNRY
Device classClass II
Decision dateJan 14, 2025
DecisionSubstantially Equivalent
Regulation870.1250
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Zoom System is a catheter-based thrombectomy device for treating acute ischemic stroke caused by large vessel occlusions in the brain. It consists of aspiration catheters (Zoom 71, 55, 45, 35), large distal platform catheters, aspiration tubing, and a vacuum pump that work together to retrieve blood clots within 8 hours of symptom onset in patients ineligible for or unresponsive to intravenous thrombolytic therapy.

Technological characteristics

The subject Zoom Catheters share identical dimensions, materials, tip design, and sterilization methods with the predicate ZOOM Reperfusion Catheters. The LDP Catheters are identical to reference devices. The main difference is the Zoom POD Aspiration Tubing adds an in-line clot filter (collection pod) compared to the predicate tubing, which had no filter. All catheters use the same medical-grade polymers with hydrophilic coating and are sterilized via ethylene oxide to a 10⁻⁶ SAL.

Test standards cited

ISO 10555-1 (catheter performance), ISO 10993-1 (biocompatibility evaluation and testing), ISO 11135 (ethylene oxide sterilization validation), ASTM F1980 (accelerated aging testing), and ISO 80369-7 (luer compatibility). Devices were tested for trackability, flexibility, burst pressure, coating integrity, vacuum force delivery, and clot retrieval performance.

Substantial equivalence argument

The predicate and subject devices share the same indications for use, intended mechanism (aspiration thrombectomy), and core design—single lumen catheters with braid/coil reinforcement, hydrophilic coating, and identical dimensions and materials. Bench testing confirmed equivalent performance in delivery, flexibility, burst resistance, and vacuum force at the catheter tip. The addition of an in-line clot filter to the POD tubing was evaluated via biocompatibility testing (cytotoxicity, sensitization, irritation) and confirmed to introduce no new safety concerns. Clinical data from the Imperative Trial (211 subjects, 84% reperfusion success rate, 0.9% symptomatic ICH) demonstrated safety and effectiveness comparable to the predicate device's historical performance, meeting all pre-specified performance goals.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →